Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

NCT05215548 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05215548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 27, 2021
Completion date
October 31, 2027
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv